177 related articles for article (PubMed ID: 37749283)
1. Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy.
Pretta A; Ziranu P; Giampieri R; Pinna G; Randon G; Donisi C; Ravarino A; Loi F; Deias G; Palmas E; Pretta G; Morano F; Semonella F; Mariani S; Deidda MA; Pusceddu V; Puzzoni M; Lai E; Solinas C; Restivo A; Zorcolo L; Barbara R; Berardi R; Faa G; Pietrantonio F; Scartozzi M
Br J Cancer; 2023 Nov; 129(10):1619-1624. PubMed ID: 37749283
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients.
Ni K; Zhan Y; Liu Z; Zhao XZ; Wang W; Wang G; Zhang Z; Li G; Zhang X; Zhang C
J Surg Oncol; 2022 Mar; 125(4):692-702. PubMed ID: 34918842
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy.
Shi S; Zhou M; Wang G; Xu J; Zhang D; Zheng M; Zhang S
Cancer Control; 2023; 30():10732748231214936. PubMed ID: 38008773
[TBL] [Abstract][Full Text] [Related]
4. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
5. The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.
Wu Z; Hu H; Wang C; Zhang J; Cai Y; Xie X; Huang Y; Deng Y
Ann Transl Med; 2022 Apr; 10(8):491. PubMed ID: 35571401
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.
Han K; Tang JH; Liao LE; Jiang W; Sui QQ; Xiao BY; Li WR; Hong ZG; Li Y; Kong LH; Li DD; Zhang XS; Pan ZZ; Steele SR; Ding PR
Dis Colon Rectum; 2023 Oct; 66(10):e996-e1005. PubMed ID: 35485833
[TBL] [Abstract][Full Text] [Related]
7. Locally advanced rectal cancer patients with mismatch repair protein deficiency can obtain better pathological response after regional chemoembolization.
Gao Y; Xiao H; Meng W; Liao J; Chen Q; Zhao G; Li C; Bai L
Front Oncol; 2023; 13():1131690. PubMed ID: 37182172
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study.
Xu L; Cai S; Xiao T; Chen Y; Qiu H; Wu B; Lin G; Sun X; Lu J; Zhou W; Xiao Y
Colorectal Dis; 2017 Jul; 19(7):O263-O271. PubMed ID: 28603932
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
[TBL] [Abstract][Full Text] [Related]
11. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Cercek A; Dos Santos Fernandes G; Roxburgh CS; Ganesh K; Ng S; Sanchez-Vega F; Yaeger R; Segal NH; Reidy-Lagunes DL; Varghese AM; Markowitz A; Wu C; Szeglin B; Sauvé CG; Salo-Mullen E; Tran C; Patel Z; Krishnan A; Tkachuk K; Nash GM; Guillem J; Paty PB; Shia J; Schultz N; Garcia-Aguilar J; Diaz LA; Goodman K; Saltz LB; Weiser MR; Smith JJ; Stadler ZK
Clin Cancer Res; 2020 Jul; 26(13):3271-3279. PubMed ID: 32144135
[TBL] [Abstract][Full Text] [Related]
12. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
[No Abstract] [Full Text] [Related]
13. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
14. Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma.
Heran M; Renaud F; Louvet C; Piessen G; Voron T; Lefèvre M; Dubreuil O; André T; Svrcek M; Cohen R
Dig Liver Dis; 2023 Feb; 55(2):276-282. PubMed ID: 35780065
[TBL] [Abstract][Full Text] [Related]
15. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Chen L; Yang X; Zhang Y; Liu J; Jiang Q; Ji F; Gao J; Zhou Z; Wang H; Huang J; Fu C
Front Oncol; 2022; 12():920916. PubMed ID: 36003789
[TBL] [Abstract][Full Text] [Related]
17. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
18. Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Meillan N; Vernerey D; Lefèvre JH; Manceau G; Svrcek M; Augustin J; Fléjou JF; Lascols O; Simon JM; Cohen R; Maingon P; Bachet JB; Huguet F
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):824-833. PubMed ID: 31404579
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
20. A Predictive Model to Evaluate Pathologic Complete Response in Rectal Adenocarcinoma.
Qing S; Gu L; Du T; Yin X; Zhang KJ; Zhang HJ
Technol Cancer Res Treat; 2023; 22():15330338231202893. PubMed ID: 37750231
[No Abstract] [Full Text] [Related]
[Next] [New Search]
